(VTR) Ventas - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US92276F1003
Stock: Senior Housing, Medical Buildings, Research Centers
Total Rating 51
Risk 28
Buy Signal 0.05
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.77% |
| Yield on Cost 5y | 4.73% |
| Yield CAGR 5y | 1.63% |
| Payout Consistency | 96.7% |
| Payout Ratio | 5.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 19.1% |
| Relative Tail Risk | -6.09% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.49 |
| Alpha | 32.54 |
| Character TTM | |
|---|---|
| Beta | 0.244 |
| Beta Downside | 0.352 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.18% |
| CAGR/Max DD | 1.07 |
Description: VTR Ventas December 17, 2025
Ventas, Inc. (NYSE: VTR) is a S&P 500-listed REIT that focuses on senior housing, outpatient medical facilities, research centers, and other healthcare-related properties across North America and the United Kingdom. With roughly 1,400 assets-including more than 850 senior-living communities-the company positions itself as a core participant in the “longevity economy,” aiming to generate superior returns through operational expertise, data-driven insights from its Ventas OI platform, and a strong balance sheet.
Key metrics that analysts watch include a FY 2023 adjusted funds from operations (AFFO) growth of about 5% YoY, an occupancy rate that has steadied near 94% across its senior-housing portfolio, and a dividend yield hovering around 5.2%, which is attractive in a low-interest-rate environment. The sector’s performance is also driven by macro trends such as the U.S. aging population-projected to add ~10 million people over 65 by 2030-and the continued shift toward outpatient care, which compresses cap rates for high-quality healthcare REITs.
For a deeper dive into VTR’s valuation metrics, the ValueRay platform offers a concise, data-rich overview.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 238.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.19 > 1.0 |
| NWC/Revenue: -8.89% < 20% (prev 6.51%; Δ -15.40% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.55b > Net Income 238.0m |
| Net Debt (12.60b) to EBITDA (2.15b): 5.87 < 3 |
| Current Ratio: 0.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (463.4m) vs 12m ago 10.48% < -2% |
| Gross Margin: 41.97% > 18% (prev 0.43%; Δ 4154 % > 0.5%) |
| Asset Turnover: 21.25% > 50% (prev 18.94%; Δ 2.31% > 0%) |
| Interest Coverage Ratio: 1.07 > 6 (EBITDA TTM 2.15b / Interest Expense TTM 752.5m) |
Altman Z'' -1.87
| A: -0.02 (Total Current Assets 849.3m - Total Current Liabilities 1.34b) / Total Assets 26.93b |
| B: -0.27 (Retained Earnings -7.37b / Total Assets 26.93b) |
| C: 0.03 (EBIT TTM 808.6m / Avg Total Assets 26.14b) |
| D: -1.01 (Book Value of Equity -14.66b / Total Liabilities 14.50b) |
| Altman-Z'' Score: -1.87 = D |
Beneish M -2.90
| DSRI: 1.04 (Receivables 446.1m/371.8m, Revenue 5.56b/4.80b) |
| GMI: 1.02 (GM 41.97% / 42.61%) |
| AQI: 1.04 (AQ_t 0.95 / AQ_t-1 0.92) |
| SGI: 1.16 (Revenue 5.56b / 4.80b) |
| TATA: -0.05 (NI 238.0m - CFO 1.55b) / TA 26.93b) |
| Beneish M-Score: -2.90 (Cap -4..+1) = A |
What is the price of VTR shares?
As of February 07, 2026, the stock is trading at USD 82.55 with a total of 3,275,599 shares traded.
Over the past week, the price has changed by +6.28%, over one month by +8.42%, over three months by +10.81% and over the past year by +40.21%.
Over the past week, the price has changed by +6.28%, over one month by +8.42%, over three months by +10.81% and over the past year by +40.21%.
Is VTR a buy, sell or hold?
Ventas has received a consensus analysts rating of 4.45.
Therefore, it is recommended to buy VTR.
- StrongBuy: 12
- Buy: 5
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the VTR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 85.9 | 4.1% |
| Analysts Target Price | 85.9 | 4.1% |
| ValueRay Target Price | 97.1 | 17.7% |
VTR Fundamental Data Overview February 03, 2026
P/E Trailing = 143.8333
P/E Forward = 131.5789
P/S = 6.5808
P/B = 2.9209
P/EG = 1.7374
Revenue TTM = 5.56b USD
EBIT TTM = 808.6m USD
EBITDA TTM = 2.15b USD
Long Term Debt = 12.57b USD (from longTermDebt, last quarter)
Short Term Debt = 107.3m USD (from shortTermDebt, last quarter)
Debt = 12.79b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.60b USD (from netDebt column, last quarter)
Enterprise Value = 49.08b USD (36.48b + Debt 12.79b - CCE 188.6m)
Interest Coverage Ratio = 1.07 (Ebit TTM 808.6m / Interest Expense TTM 752.5m)
EV/FCF = 42.60x (Enterprise Value 49.08b / FCF TTM 1.15b)
FCF Yield = 2.35% (FCF TTM 1.15b / Enterprise Value 49.08b)
FCF Margin = 20.74% (FCF TTM 1.15b / Revenue TTM 5.56b)
Net Margin = 4.28% (Net Income TTM 238.0m / Revenue TTM 5.56b)
Gross Margin = 41.97% ((Revenue TTM 5.56b - Cost of Revenue TTM 3.22b) / Revenue TTM)
Gross Margin QoQ = 41.58% (prev 41.80%)
Tobins Q-Ratio = 1.82 (Enterprise Value 49.08b / Total Assets 26.93b)
Interest Expense / Debt = 2.34% (Interest Expense 299.7m / Debt 12.79b)
Taxrate = 21.0% (US default 21%)
NOPAT = 638.8m (EBIT 808.6m * (1 - 21.00%))
Current Ratio = 0.63 (Total Current Assets 849.3m / Total Current Liabilities 1.34b)
Debt / Equity = 1.03 (Debt 12.79b / totalStockholderEquity, last quarter 12.36b)
Debt / EBITDA = 5.87 (Net Debt 12.60b / EBITDA 2.15b)
Debt / FCF = 10.93 (Net Debt 12.60b / FCF TTM 1.15b)
Total Stockholder Equity = 11.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.91% (Net Income 238.0m / Total Assets 26.93b)
RoE = 2.06% (Net Income TTM 238.0m / Total Stockholder Equity 11.53b)
RoCE = 3.35% (EBIT 808.6m / Capital Employed (Equity 11.53b + L.T.Debt 12.57b))
RoIC = 2.61% (NOPAT 638.8m / Invested Capital 24.50b)
WACC = 5.52% (E(36.48b)/V(49.27b) * Re(6.81%) + D(12.79b)/V(49.27b) * Rd(2.34%) * (1-Tc(0.21)))
Discount Rate = 6.81% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 6.71%
[DCF Debug] Terminal Value 87.44% ; FCFF base≈1.00b ; Y1≈1.13b ; Y5≈1.52b
Fair Price DCF = 68.55 (EV 44.80b - Net Debt 12.60b = Equity 32.20b / Shares 469.7m; r=5.90% [WACC]; 5y FCF grow 14.74% → 2.90% )
EPS Correlation: 34.13 | EPS CAGR: -8.86% | SUE: -0.94 | # QB: 0
Revenue Correlation: 97.51 | Revenue CAGR: 10.54% | SUE: 3.72 | # QB: 5
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=-0.007 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=0.56 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=+109.3% | Growth Revenue=+15.5%
P/E Forward = 131.5789
P/S = 6.5808
P/B = 2.9209
P/EG = 1.7374
Revenue TTM = 5.56b USD
EBIT TTM = 808.6m USD
EBITDA TTM = 2.15b USD
Long Term Debt = 12.57b USD (from longTermDebt, last quarter)
Short Term Debt = 107.3m USD (from shortTermDebt, last quarter)
Debt = 12.79b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.60b USD (from netDebt column, last quarter)
Enterprise Value = 49.08b USD (36.48b + Debt 12.79b - CCE 188.6m)
Interest Coverage Ratio = 1.07 (Ebit TTM 808.6m / Interest Expense TTM 752.5m)
EV/FCF = 42.60x (Enterprise Value 49.08b / FCF TTM 1.15b)
FCF Yield = 2.35% (FCF TTM 1.15b / Enterprise Value 49.08b)
FCF Margin = 20.74% (FCF TTM 1.15b / Revenue TTM 5.56b)
Net Margin = 4.28% (Net Income TTM 238.0m / Revenue TTM 5.56b)
Gross Margin = 41.97% ((Revenue TTM 5.56b - Cost of Revenue TTM 3.22b) / Revenue TTM)
Gross Margin QoQ = 41.58% (prev 41.80%)
Tobins Q-Ratio = 1.82 (Enterprise Value 49.08b / Total Assets 26.93b)
Interest Expense / Debt = 2.34% (Interest Expense 299.7m / Debt 12.79b)
Taxrate = 21.0% (US default 21%)
NOPAT = 638.8m (EBIT 808.6m * (1 - 21.00%))
Current Ratio = 0.63 (Total Current Assets 849.3m / Total Current Liabilities 1.34b)
Debt / Equity = 1.03 (Debt 12.79b / totalStockholderEquity, last quarter 12.36b)
Debt / EBITDA = 5.87 (Net Debt 12.60b / EBITDA 2.15b)
Debt / FCF = 10.93 (Net Debt 12.60b / FCF TTM 1.15b)
Total Stockholder Equity = 11.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.91% (Net Income 238.0m / Total Assets 26.93b)
RoE = 2.06% (Net Income TTM 238.0m / Total Stockholder Equity 11.53b)
RoCE = 3.35% (EBIT 808.6m / Capital Employed (Equity 11.53b + L.T.Debt 12.57b))
RoIC = 2.61% (NOPAT 638.8m / Invested Capital 24.50b)
WACC = 5.52% (E(36.48b)/V(49.27b) * Re(6.81%) + D(12.79b)/V(49.27b) * Rd(2.34%) * (1-Tc(0.21)))
Discount Rate = 6.81% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 6.71%
[DCF Debug] Terminal Value 87.44% ; FCFF base≈1.00b ; Y1≈1.13b ; Y5≈1.52b
Fair Price DCF = 68.55 (EV 44.80b - Net Debt 12.60b = Equity 32.20b / Shares 469.7m; r=5.90% [WACC]; 5y FCF grow 14.74% → 2.90% )
EPS Correlation: 34.13 | EPS CAGR: -8.86% | SUE: -0.94 | # QB: 0
Revenue Correlation: 97.51 | Revenue CAGR: 10.54% | SUE: 3.72 | # QB: 5
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=-0.007 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=0.56 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=+109.3% | Growth Revenue=+15.5%